Back
ESC Premium Access

Positioning of the topic - The PCSK9 story .. so far

Session: Do we need PCSK9 inhibitors in post-MI patients?
Topic: Drug therapy
Speaker: Professor F. Mach (Geneva, CH)
Event: ESC Congress 2017

Congress Presentation

Add to my library

Like

About the speaker

Professor Francois Mach

University hospitals of Geneva, Geneva (Switzerland)
24 presentations
14 followers

7 more presentations in this session

Opening question.

Access
Slides
Video
Like
Thumbnail

Do we need PCSK9 inhibitors in post-MI patients? PRO

Speaker: Professor M. Sabatine (Boston, US)

Access
Slides
Video
Like
Thumbnail

Do we need PCSK9 inhibitors in post-MI patients? CON

Speaker: Professor H. Drexel (Feldkirch, AT)

Access
Slides
Video
Like
Thumbnail

Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO

Speaker: Professor M. Sabatine (Boston, US)

Access
Video
Like
Thumbnail

Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON

Speaker: Professor H. Drexel (Feldkirch, AT)

Access
Video
Like
Thumbnail

Access the full session

Do we need PCSK9 inhibitors in post-MI patients?

Speakers: Professor F. Mach, Professor M. Sabatine, Professor H. Drexel, Professor M. Sabatine, Professor H. Drexel
Access
Like
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources